Dear Editor,
Patients with ARDS due to COVID-19 are characterised by poor oxygenation with a various extent of pulmonary alterations [
1]. Ventilation strategies for COVID-19 patients have been suggested basing on the pathophysiological evidence to date [
1]; however, there are no data regarding the use of inhaled nitric oxide (iNO). We report herein our experience of iNO administration in COVID-19 mechanically ventilated patients with refractory hypoxaemia and/or right ventricular (RV) dysfunction. Refractory hypoxaemia was defined as PaO
2/FiO
2 < 100 despite high PEEP (≥ 10 cmH
2O) and prone position. RV dysfunction was defined as acute
cor pulmonale at echocardiography with hemodynamic impairment requiring infusion of inotropic drugs [
2].
The NO/nitrogen mixture was introduced into the inspiratory limb of the ventilator tubing. Respiratory and haemodynamic parameters were collected immediately before iNO administration (
t0) and after 15–30 min (
t1). Responders were defined by an increase of PaO
2/FiO
2 > 20% compared to
t0 [
3].
Results in the text are shown as median [IQR] or number (%). Wilcoxon test for paired samples and Mann-Whitney test, as appropriate (MedCalc version 19.2 MedCalc Software), were performed considering p < 0.05 as significant.
iNO was used in sixteen out of 72 (22.2%) consecutive mechanically ventilated patients (66.0 [59.6–69.7] years old; 93% male). All patients required iNO for refractory hypoxaemia of whom 4 (25%) had also superimposed RV dysfunction, in 1 case associated with pulmonary embolism. The iNO dosage was 25 [20–30] parts per million (ppm).
Respiratory parameters at
t0 and
t1 are shown in Table
1. Overall, iNO did not improve oxygenation in our population. Only 4 (25%) patients were responders, of whom 3 have superimposed RV dysfunction, showing a median increase of PaO
2/FiO
2 of 26.9% [24.1–45.5]. A trend towards a larger improvement of oxygenation was observed in patients with RV dysfunction as compared with those without (PaO
2/FiO
2 increase 24.1% [9.2–43.5] vs. 3.3% [− 10.8–11.5],
p = 0.069). Additionally, in responders, PaO
2/FiO
2 was 125.9 [82.2–259.2] at
t1 and did not change (
p = 0.875) 24 h later (146.4 [102.2–225.1]).
Table 1
Patients respiratory and hemodynamic parameters at the two time points
SBP, mmHg | 127.0 [114.0–137.5] | 119.0 [110.0–138.0] | 0.454 |
MAP, mmHg | 83.5 [80.5–93.5] | 78.0 [74.5–85.5] | 0.144 |
HR, bpm | 89.5 [80.5–99.7] | 88.0 [75.0–100.0] | 0.159 |
pH | 7.27 [7.22–7.35] | 7.31 [7.24–7.36] | 0.049 |
PaCO2, mmHg | 59.8 [52.5–76.5] | 60.9 [50.8–65.7] | 0.002 |
PaO2, mmHg | 79.7 [58.9–87.2] | 77.1 [63.5–88.6] | 0.252 |
PaO2/FiO2 | 91.7 [62.1–109.2] | 91.5 [67.1–106.7] | 0.274 |
MetHb, % | 1.18 [1–1.3] | 1.3 [1.1–1.4] | 0.16 |
FiO2 | 87.5 [80–95] | 87.5 [80–95] | 1 |
PEEP, cmH2O | 13.0 [10.0–15.0] | 13.0 [10.0–15.0] | 1 |
MV, L/min | 9.7 [8.1–11.3] | 10.3 [8.7–11.4] | 0.204 |
Peak pressure, cmH2O | 30.5 [27.5–33.5] | 30.5 [26.0–33.0] | 0.641 |
iNO is a free radical gas that diffuses across the alveolar-capillary membrane into the subjacent smooth muscle of pulmonary vessels enhancing endothelium-dependent vasorelaxation and improving oxygenation by increasing blood flow to ventilated lung units [
3]. In previous studies, iNO was effective in improving PaO
2/FiO
2 and oxygenation index, although it failed in reversing acute lung injury, reducing mechanical ventilation days and mortality [
4].
In our population, the improvement of oxygenation in responders was probably magnified by an iNO-induced decrease of RV afterload, enhancing cardiac output and finally leading to an increase of mixed venous oxygen saturation.
Although the reason why patients with refractory hypoxaemia without RV dysfunction were not responder is yet to be determined, some speculation can be done. Severe endothelial injury with cytoplasmic vacuolization and cell detachment in pulmonary middle-small arteries can make the pulmonary vessels less reactive to iNO stimulation [
1,
5,
6]. This could also explain the loss of hypoxic vasoconstriction and lung perfusion regulation. However, whether vascular derangements in COVID-19 are due to endothelial cell involvement by the virus, part of the ARDS pathophysiology or the intertwine of both is still undetermined. Moreover, prone position and iNO were used in refractory hypoxaemia as an escalating treatment strategy. Therefore, a positive response to the prone position may have precluded the enrolment in our study of patients that could positively respond to iNO.
Conclusion
Overall, iNO did not improve oxygenation in COVID-19 patients with refractory hypoxaemia, when administered as a rescue treatment after prone position. A subgroup of patients with RV dysfunction was better iNO responders probably due to the haemodynamic improvement associated with RV unloading.
Acknowledgements
We thank all the nurses and physicians involved in the management of such epidemics (Dr. Camporotondo Rita, Prof. Iotti Giorgio, Dr. Sciutti Fabio, Dr. Rodi Giuseppe, Dr. Orlando Anita, Dr. Maggio Giuseppe, Dr. Belliato Mirko, Dr. Radolovich Danila, Dr. Sala Gallini Giuseppe, Dr. Caneva Luca, Dr. Pagani Michele, Dr.Ferrari Fiorenza, Dr. Aliberti Anna, Dr. Visconti Federico, Dr. Repossi Filippo, Dr. Civardi Luca, Dr. Puce Roberta, Dr. Aliberti Anna, Dr.Bottazzi, Andrea, Dr. Amatu Alessandro, Dr. Lococo Claudia, Dr. Arisi Eric) and the Pavia COVID-19 Task Force (Dr. Marena Carlo, Dr. Calvi Monica, Dr. Grugnetti Giuseppina, Dr. Maurelli Marco, Dr. Muzzi Alba, Prof. Raffaele Bruno, Dr. Lago Paolo, Prof. Marseglia Gianluigi, Prof. Perlini Stefano, Dr. Palo Alessandra, Prof Baldanti Fausto, Prof. Corsico Angelo Guido, Prof. Di Sabatino Antonio, Prof. Iotti Giorgio, Prof. Benazzo Marco, Prof.Carlo Nicora, Prof.Antonio Triarico and Dr. Vincenzo Petronella).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.